Clinical trials: Urinary System Disorder
Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection
Open-Label Extension of CP101 Trials Evaluating Oral Full-Spectrum Microbiota™ (CP101) in Subjects With Recurrence of Clostridium Difficile Infection
This is an open-label study evaluating the safety and efficacy of CP101 treatment in 1) Subjects in CDI-001 who had a CDI recurrence within 8 weeks of receiving CP101 or placebo; OR 2) adults with recurrent CDI who are eligible…
- Conditions
- Clostridium Difficile Infection, Recurrent Clostridium Difficile Infection, C. Diff, CDI
- Trial name
- PRISM-EXT (NCT03497806)
- Testing
- CP101
- Where
- 57 sites in United States, Canada
- Volunteers
- 132 people
- Sponsor
- Finch Research and Development LLC.
Bladder, Neurogenic
PK/PD, Long-term Safety and Efficacy of Tamsulosin Treatment in Children With Neurogenic Bladder
Aims of this study is to characterize the pharmacokinetic/pharmacodynamic profile and evaluate the safety, efficacy and tolerability, of tamsulosin hydrochloride as treatment in children with a neuropathic bladder, over the…
- Trial name
- NCT00340704
- Testing
- tamsulosin hydrochloride
- Where
- 72 sites in United States, Belgium and 12 more
- Volunteers
- 143 people
- Sponsor
- Boehringer Ingelheim
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Solid Tumours
Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment
The purpose of this study is to assess the effect of severe renal impairment on the levels of AZD9291 in the blood in patients with advanced solid tumours compared to patients with normal renal function
- Trial name
- NCT02923947
- Testing
- Osimertinib; AZD9291
- Where
- 11 sites in France, South Korea and 1 more
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Solid Tumor, Soft Tissue Sarcoma
A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors
This clinical study is to investigate the safety and tolerability of CAR modified autologous T cells (CCT301-59) in subjects with recurrent or refractory solid tumors.
- Conditions
- Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer
- Trial name
- CAR (NCT03960060)
- Testing
- CCT301-59
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Shanghai PerHum Therapeutics Co., Ltd.
Normal and Impaired Renal Function
A Phase 1 Study Investigating the Safety and Pharmacokinetics of Repeat-dose Intravenous Infusion of MTP-131 in Subjects With Impaired Renal Function
This study is a Phase 1, open-label, parallel group, multiple dose study, in subjects over 18 years, to evaluate the safety, tolerability, and pharmacokinetics of one-hour intravenous infusion of MTP-131 administered for 7…
- Trial name
- NCT02436447
- Testing
- MTP-131
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Stealth BioTherapeutics Inc.
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Cancer Harboring BRAF Alterations, HGG
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with BRAF altered (BRAF V600E or BRAF fusions) locally advanced or metastatic solid tumors, or recurrent or progressive…
- Conditions
- Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors
- Trial name
- NCT05503797
- Testing
- Plixorafenib
- Where
- 70 sites in United States, Australia and 10 more
- Volunteers
- 254 people
- Sponsor
- Fore Biotherapeutics
Chronic Kidney Disease, Type 2 Diabetes
A Glomerular Filtration Rate (GFR) Measuring Study of RTA 402 in Chronic Kidney Disease (CKD) Patients With Type 2 Diabetes Mellitus
A Phase 2 glomerular filtration rate (GFR) measuring study of RTA 402 in Chronic kidney disease (CKD) patients with type 2 diabetes mellitus.
- Trial name
- NCT01572610
- Testing
- RTA 402
- Where
- Japan
- Volunteers
- 11 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Melanoma, Lung Cancer
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of BCD-100 in Patients With Advanced Solid Tumors
A Multicenter Open-Label Single-Arm Multi-Cohort Phase I Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) in Patients with Advanced Solid Tumors
- Conditions
- Melanoma, Lung Cancer, Renal Cell Carcinoma
- Trial name
- NCT03050047
- Testing
- BCD-100
- Where
- 4 sites in Russia
- Volunteers
- 15 people
- Sponsor
- Biocad
Impaired Renal Function
Study of SSP-004184 (FBS0701) in Healthy Adults and Elderly Subjects and in Subjects With Impaired Renal Function
Shire is developing SSP-004184 (FBS0701), a novel iron chelator , for the treatment of chronic iron overload in patients with transfusion-dependent hereditary and acquired anemias.
- Trial name
- NCT01716455
- Testing
- SSP-004184
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Shire
Chronic Kidney Disease
To Determine the Accuracy of SCreening for Occult REnal Disease (SCORED) Questionnaire for CKD Risk Among Asian Patients
To determine the accuracy of SCreening for Occult REnal Disease (SCORED) questionnaire for CKD risk among Asian Patients
- Trial name
- SCREEN (NCT05866276)
- Where
- 3 sites in Indonesia, Vietnam
- Volunteers
- 1,426 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
This is a first-in-human (FIH), open-label, multi-site study which will evaluate the safety, efficacy, tolerability, pharmacokinetics (PK), and immunogenicity of increasing doses of BNT317 in participants with advanced solid…
- Trial name
- NCT06750185
- Testing
- BNT317 DL1, BNT317 DL2, BNT317 DL3
- Where
- 11 sites in United States, Australia
- Volunteers
- 248 people
- Sponsor
- BioNTech SE
Uncontrolled Hypertension
Effect of the MobiusHD® in Renal Hemodialysis Subjects With Uncontrolled Hypertension
This is a prospective, multi-center, open-label clinical trial intended to evaluate the safety and benefit of the MobiusHD® system in renal hemodialysis subjects with uncontrolled hypertension.
- Trial name
- HD (NCT05352425)
- Testing
- MobiusHD
- Sponsor
- Vascular Dynamics, Inc.
Respiratory Tract Infections, Urinary Tract Infections
Study on Cefotaxime and Sulbactam Sodium for Injection (2:1) for Treatment of Respiratory and Urinary Tract Infection
In the proposed study, the investigators plan to evaluate the efficacy and safety of Cefotaxime sodium and sulbactam sodium for injection (2:1)for the treatment of respiratory and urinary tract acute bacterial infection under the…
- Trial name
- SWSB (NCT01426191)
- Testing
- xinzhijun
- Volunteers
- 2,032 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Diabetic Kidney Disease, IgA Nephropathy
A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease
This is a phase II study to investigate the safety, preliminary efficacy and pharmacokinetics of SC0062 capsule in patients with chronic kidney disease (diabetic kidney disease and IgA nephropathy)with albuminuria compared to…
- Trial name
- NCT05687890
- Testing
- SC0062 low dose, SC0062 medium dose, SC0062 high dose
- Where
- China
- Volunteers
- 255 people
- Sponsor
- Biocity Biopharmaceutics Co., Ltd.
Renal Cell Carcinoma
Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no…
- Trial name
- NCT03142334
- Testing
- Pembrolizumab
- Where
- 251 sites in United States, Argentina and 19 more
- Volunteers
- 994 people
- Sponsor
- Merck Sharp & Dohme LLC
Bladder Cancer, Urothelial Carcinoma
A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer
This Phase 3, single-arm, multicenter study was designed to evaluate the efficacy and safety of UGN-103, a novel formulation of UGN-102, instilled in the urinary bladder of patients with recurrent low-grade intermediate-risk…
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder
- Trial name
- UTOPIA (NCT06331299)
- Testing
- UGN-103
- Where
- 48 sites in United States, Bulgaria and 5 more
- Volunteers
- 99 people
- Sponsor
- UroGen Pharma Ltd.
Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors.
- Conditions
- Cervical Cancer, Gastric/Gastroesophageal Junction Adenocarcinoma, Microsatellite Stable Colorectal Cancer, Non-Small-Cell Lung Cancer
- Trial name
- NCT04895709
- Testing
- BMS-986340, BMS-936558-01, Docetaxel
- Where
- 47 sites in United States, Australia and 6 more
- Volunteers
- 1,109 people
- Sponsor
- Bristol-Myers Squibb
Hepatocellular Carcinoma, Renal Cell Carcinoma
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
Study Design and Investigational Plan: This is an open-label Phase 1/2 study to assess the safety and tolerability of combination PD-1 inhibitor (APL-501 or nivolumab) administered concomitantly with c-Met inhibitor (APL-101), to…
- Trial name
- NCT03655613
- Testing
- APL-501, APL-101, Nivolumab
- Where
- 9 sites in Australia, New Zealand
- Volunteers
- 20 people
- Sponsor
- Apollomics (Australia) Pty. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.